Overexpression of hypoxia‑inducible factor‑1α and vascular endothelial growth factor in sacral giant cell tumors and the correlation with tumor microvessel density

Fu,Shaofeng; Bai,Rui; Zhao,Zhenqun; Zhang,Zhifeng; Zhang,Gang; Wang,Yuxin; Wang,Yong; Jiang,Dianming; Zhu,Dezhi

doi:10.3892/etm.2014.1971

Overexpression of hypoxia‑inducible factor‑1α and vascular endothelial growth factor in sacral giant cell tumors and the correlation with tumor microvessel density

Authors:
- Shaofeng Fu
- Rui Bai
- Zhenqun Zhao
- Zhifeng Zhang
- Gang Zhang
- Yuxin Wang
- Yong Wang
- Dianming Jiang
- Dezhi Zhu
View Affiliations

Affiliations: Graduate School of Chongqing Medical University, Chongqing 400331, P.R. China, Department of Pediatric Orthopedics, Second Affiliated Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolian Autonomous Region 010050, P.R. China, Department of Orthopedics, Second Affiliated Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolian Autonomous Region 010050, P.R. China, Department of Orthopedics, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, Department of Orthopedics, Fourth Hospital of Inner Mongolia Autonomous Region, Huhhot, Inner Mongolian Autonomous Region 010030, P.R. China
Published online on: September 17, 2014 https://doi.org/10.3892/etm.2014.1971
Pages: 1453-1458

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although classified as benign, giant cell tumors of the bone (GCTB) may be aggressive, recur and even metastasize to the lungs. In addition, the pathogenesis and histogenesis remain unclear; thus, the driving factors behind the strong tumor growth capacity of GCTB require investigation. In the present study, the expression levels of hypoxia‑inducible factor (HIF)‑1α and vascular endothelial growth factor (VEGF), which are promoted by hypoxic conditions, were determined in 22 sacral GCTB samples using immunohistochemistry and western blot analysis. Furthermore, CD34 expression was analyzed using these methods. The correlation between HIF‑1α or VEGF expression and the tumor microvessel density (MVD) was then determined. The results demonstrated that HIF‑1α, VEGF and CD34 were overexpressed in the 22 sacral GCTB specimens, and overexpression of HIF‑1α and VEGF correlated with the tumor MVD. Thus, the present study has provided novel indicators for the tumor growth capacity of GCTBs.

View Figures

View References

1	Anract P, De Pinieux G, Cottias P, Pouillart P, Forest M and Tomeno B: Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: a review of 29 cases. Int Orthop. 22:19–26. 1998. View Article : Google Scholar : PubMed/NCBI
2	Gamberi G, Serra M, Ragazzini P, et al: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 10:351–356. 2003.PubMed/NCBI
3	Miszczyk L, Wydmański J and Spindel J: Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys. 49:1239–1242. 2001. View Article : Google Scholar : PubMed/NCBI
4	Turcotte RE, Sim FH and Unni KK: Giant cell tumor of the sacrum. Clin Orthop Relat Res. 291:215–221. 1993.PubMed/NCBI
5	Turcotte RE: Giant cell tumor of bone. Orthop Clin North Am. 37:35–51. 2006. View Article : Google Scholar
6	Sung HW, Shu WP, Wang HM, Yuai SY and Tsai YB: Surgical treatment of primary tumors of the sacrum. Clin Orthop Relat Res. 215:91–98. 1987.PubMed/NCBI
7	Guo W, Ji T, Tang X and Yang Y: Outcome of conservative surgery for giant cell tumor of the sacrum. Spine (Phila Pa 1976). 34:1025–1031. 2009. View Article : Google Scholar : PubMed/NCBI
8	McDonald DJ, Sim FH, McLeod RA and Dahlin DC: Giant-cell tumor of bone. J Bone Joint Surg Am. 68:235–242. 1986.PubMed/NCBI
9	Campanacci M, Baldini N, Boriani S and Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am. 69:106–114. 1987.PubMed/NCBI
10	Olivera P, Perez E, Ortega A, et al: Estrogen receptor expression in giant cell tumors of the bone. Hum Pathol. 33:165–169. 2002. View Article : Google Scholar : PubMed/NCBI
11	Morgan T, Atkins GJ, Trivett MK, et al: Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol. 167:117–128. 2005. View Article : Google Scholar : PubMed/NCBI
12	Skubitz KM, Cheng EY, Clohisy DR, Thompson RC and Skubitz AP: Gene expression in giant-cell tumors. J Lab Clin Med. 144:193–200. 2004. View Article : Google Scholar : PubMed/NCBI
13	Atkins GJ, Haynes DR, Graves SE, et al: Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res. 15:640–649. 2000. View Article : Google Scholar : PubMed/NCBI
14	Cummins EP and Taylor CT: Hypoxia-responsive transcription factors. Pflugers Arch. 450:363–371. 2005. View Article : Google Scholar : PubMed/NCBI
15	Licausi F, Weits DA, Pant BD, Scheible WR, Geigenberger P and van Dongen JT: Hypoxia responsive gene expression is mediated by various subsets of transcription factors and miRNAs that are determined by the actual oxygen availability. New Phytol. 190:442–456. 2011. View Article : Google Scholar : PubMed/NCBI
16	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
17	Christofk HR, Vander Heiden MG, Harris MH, et al: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 452:230–233. 2008. View Article : Google Scholar : PubMed/NCBI
18	Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. Proc Natl Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
19	Pouysségur J, Dayan F and Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 441:437–443. 2006.PubMed/NCBI
20	Kaelin WG Jr and Ratcliffe PJ: Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 30:393–402. 2008. View Article : Google Scholar : PubMed/NCBI
21	Blancher C, Moore JW, Talks KL, Houlbrook S and Harris AL: Relationship of hypoxia-inducible factor (HIF)-1alpha and hif-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 60:7106–7113. 2000.
22	Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830–5835. 1999.PubMed/NCBI
23	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
24	Pralhad T, Madhusudan S and Rajendrakumar K: Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol. 55:1045–1053. 2003. View Article : Google Scholar : PubMed/NCBI
25	Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
26	Taylor RM, Kashima TG, Knowles HJ and Athanasou NA: VEGF, FLT3 ligand, PIGF and HGF can substitute for M-CSF to induce human osteoclast formation: Implications for giant cell tumour pathobiology. Lab Invest. 92:1398–1406. 2012. View Article : Google Scholar : PubMed/NCBI
27	Saikia B, Goel A and Gupta SK: Fine-needle aspiration cytologic diagnosis of giant-cell tumor of the sacrum presenting as a rectal mass: A case report. Diagn Cytopathol. 24:39–41. 2001. View Article : Google Scholar : PubMed/NCBI
28	Hara H, Akisue T, Fujimoto T, et al: Expression of vegf and its receptors and angiogenesis in bone and soft tissue tumors. Anticancer Res. 26:4307–4311. 2006.PubMed/NCBI
29	Athanasou NA, Bliss E, Gatter KC, Heryet A, Woods CG and McGee JO: An immunohistological study of giant-cell tumour of bone: evidence for an osteoclast origin of the giant cells. J Pathol. 147:153–158. 1985. View Article : Google Scholar : PubMed/NCBI
30	Bertoni F, Present D and Enneking WF: Giant-cell tumor of bone with pulmonary metastases. J Bone Joint Surg Am. 67:890–900. 1985.PubMed/NCBI
31	Brahimi-Horn MC and Pouysségur J: Harnessing the hypoxia-inducible factor in cancer and ischemic disease. Biochem Pharmacol. 73:450–457. 2007. View Article : Google Scholar : PubMed/NCBI
32	Knowles HJ and Athanasou NA: Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol. 215:56–66. 2008. View Article : Google Scholar : PubMed/NCBI
33	Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A and Marmé D: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 87:3336–3343. 1996.PubMed/NCBI
34	Engsig MT, Chen QJ, Vu TH, et al: Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol. 151:879–889. 2000. View Article : Google Scholar : PubMed/NCBI
35	Aldridge SE, Lennard TW, Williams JR and Birch MA: Vascular endothelial growth factor receptors in osteoclast differentiation and function. Biochem Biophys Res Commun. 335:793–798. 2005. View Article : Google Scholar : PubMed/NCBI
36	Mori S, Akagi M, Kikuyama A, Yasuda Y and Hamanishi C: Axial shortening during distraction osteogenesis leads to enhanced bone formation in a rabbit model through the HIF-1alpha/vascular endothelial growth factor system. J Orthop Res. 24:653–663. 2006. View Article : Google Scholar
37	Zheng MH, Xu J, Robbins P, et al: Gene expression of vascular endothelial growth factor in giant cell tumors of bone. Hum Pathol. 31:804–812. 2000. View Article : Google Scholar : PubMed/NCBI
38	Kumta SM, Huang L, Cheng YY, Chow LT, Lee KM and Zheng MH: Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci. 73:1427–1436. 2003. View Article : Google Scholar : PubMed/NCBI
39	Brizel DM, Rosner GL, Prosnitz LR and Dewhirst MW: Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int J Radiat Oncol Biol Phys. 32:1121–1125. 1995. View Article : Google Scholar : PubMed/NCBI
40	Hill SA, Pigott KH, Saunders MI, et al: Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br J Cancer Suppl. 27:S260–S263. 1996.PubMed/NCBI
41	Cohen-Jonathan E, Evans SM, Koch CJ, et al: The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res. 61:2289–2293. 2001.PubMed/NCBI